A singe-blind, randomised, triple cross-over, single-dose pharmacokinetic and safety study of HTD1801 and its components.

Trial Profile

A singe-blind, randomised, triple cross-over, single-dose pharmacokinetic and safety study of HTD1801 and its components.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs HTD 1801 (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Pharmacokinetics
  • Sponsors HighTide Biopharma
  • Most Recent Events

    • 24 Jan 2017 Planned number of patients changed from 20 to 24.
    • 24 Jan 2017 Planned initiation date changed from 14 Jan 2017 to 13 Feb 2017.
    • 11 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top